Using its novel and proprietary technology called Expression Microdissection, xMD's technology enables the researcher and clinician to isolate, procure and enrich only those “cells of interest” (e.g. specific malignant tumor cancer cells) from biopsy and other specimen  samples. Doing so enables and facilitates downstream PCR, genomic/proteomic, NGS and molecular testing for histology and cytology specimens. Expression microdissection, therefore, represents the first enabling step in the molecular pathology workflow, and is crucial to procuring the necessary quality and quantity of cells/DNA/RNA and  for molecular testing.